37M, trading at HK$0.17 on the HKSE. This SniperIQ fundamentals page covers Sinco Pharmaceuticals Holdings's valuation (P/E 8.4x, P/B 0.4x), profitability (net margin 1.7%), revenue (¥2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
37M
P/E (TTM)8.4x
Net Margin1.7%
Revenue (FY25)¥2.1B

Full research coverage

Frequently Asked Questions

What is Sinco Pharmaceuticals Holdings's market cap?

Sinco Pharmaceuticals Holdings (6833) has a market capitalization of approximately HK

37M, trading at HK$0.17 on the HKSE. Market cap moves with the live share price.

What is Sinco Pharmaceuticals Holdings's P/E ratio?

Sinco Pharmaceuticals Holdings's trailing twelve-month P/E ratio is 8.4x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sinco Pharmaceuticals Holdings?

Sinco Pharmaceuticals Holdings runs a net profit margin of 1.7%, a gross margin of 10.7%, and an operating margin of 2.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sinco Pharmaceuticals Holdings generate?

Sinco Pharmaceuticals Holdings reported revenue of ¥2.1B for fiscal year 2025, with net income of ¥35M and earnings per share (EPS) of 0.0171. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sinco Pharmaceuticals Holdings pay a dividend?

Sinco Pharmaceuticals Holdings offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Sinco Pharmaceuticals Holdings financially healthy?

Sinco Pharmaceuticals Holdings carries a debt-to-equity ratio of 0.26x and a current ratio of 1.18x, with a market beta of 0.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sinco Pharmaceuticals Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sinco Pharmaceuticals Holdings (6833) the key facts are: market cap HK

37M, P/E 8.4x, revenue ¥2.1B, 52-week range 0.149-0.255. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Sinco Pharmaceuticals Holdings's full fundamentals live

Get Sinco Pharmaceuticals Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.